Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a late-stage clinical therapeutics company focused on developing novel medicines for patients with neuropsychiatric and other disorders. The company operates through a pipeline of intranasal pherine product candidates, each designed with a neurocircuitry-focused mechanism… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vistagen Therapeutics, Inc. does
In the company’s own words
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a late-stage clinical therapeutics company focused on developing novel medicines for patients with neuropsychiatric and other disorders. The company operates through a pipeline of intranasal pherine product candidates, each designed with a neurocircuitry-focused mechanism of action that targets peripheral nasal chemosensory neurons to modulate specific brain circuits without requiring systemic absorption or direct uptake into the brain.
The company's most advanced program is fasedienol, currently in Phase 3 clinical development for the acute treatment of social anxiety disorder under the PALISADE program, which has received FDA fast track designation. Fasedienol represents a differentiated approach to anxiety treatment, designed to provide rapid-onset relief on an as-needed basis without the abuse liability and side effects associated with benzodiazepines and other systemic neuropsychiatric medications.
Vistagen's pipeline includes four additional intranasal pherine candidates in clinical development: itruvone for major depressive disorder, refisolone for moderate to severe vasomotor symptoms due to menopause and premenstrual dysphoric disorder, PH15 for psychomotor impairment due to mental fatigue, and PH284 for cancer cachexia. The company also maintains AV-101, an oral prodrug candidate targeting NMDAR-related neurological disorders including levodopa-induced dyskinesia and neuropathic pain, though the company is currently assessing third-party development opportunities for this asset.
The company has established strategic partnerships to maximize value across its pipeline, including an exclusive license and collaboration agreement with AffaMed Therapeutics for fasedienol development and commercialization in Greater China, South Korea, and Southeast Asia. Vistagen maintains an open investigational new drug application for multiple candidates and has received FDA fast track designations for itruvone and AV-101.
The company's intellectual property portfolio includes granted and pending patents covering its product candidates' therapeutic uses, formulations, nasal administration devices, and manufacturing processes across multiple jurisdictions. Vistagen engages contract development and manufacturing organizations and contract research organizations to support its development programs while maintaining operational flexibility.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- March
- CIK
- 1411685
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vistagen Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vistagen Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vistagen Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vistagen Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vistagen Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”